Myriad Genetics ( MYGN ) Q3 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
| Ticker |
Sentiment |
Impact |
|
SGMO
|
Neutral
|
21 %
|
|
MYGN
|
Neutral
|
14 %
|
